Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:3458
Name breast adenocarcinoma
Definition A breast carcinoma that originates in the milk ducts and/or lobules (glandular tissue) of the breast.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer breast carcinoma breast adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
PIK3CA mutant Acalisib breast adenocarcinoma sensitive detail...
PTEN loss Voxtalisib breast adenocarcinoma sensitive detail...
PTEN loss Gemcitabine + LY2780301 breast adenocarcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00461773 Phase II Letrozole Bevacizumab Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer Terminated USA 0
NCT00796978 Phase II Trastuzumab Trastuzumab in Treating Older Women With Early-Stage Breast Cancer Completed USA 0
NCT00826085 Phase Ib/II ThermoDox Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall Completed USA 0
NCT01007695 Phase I Valproic acid Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot Terminated USA 0
NCT01111825 Phase Ib/II Neratinib + Temsirolimus Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer Completed USA | GBR | FRA | ESP | DNK 1
NCT01124695 Phase II Tamoxifen Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Completed USA | CAN 1
NCT01283789 Phase II Everolimus + Lapatinib Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer Unknown status USA 0
NCT01572038 Phase III Pertuzumab + Trastuzumab Nab-paclitaxel Docetaxel Paclitaxel A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE) Completed TUR | SWE | SVN | POL | NLD | LTU | LBN | ITA | ISR | HUN | GRC | GBR | FRA | FIN | EST | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG 16
NCT01697293 Phase Ib/II Paclitaxel + Triciribine Cyclophosphamide + Doxorubicin Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Terminated USA 0
NCT01724606 Phase I Sorafenib Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM) Completed USA 0
NCT01824836 Phase 0 Anastrozole A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) Active, not recruiting USA 0
NCT01862081 Phase I Docetaxel + Taselisib Paclitaxel + Taselisib A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer Completed USA | ESP | CAN | BEL 0
NCT01897441 Phase I Paclitaxel Paclitaxel + Trastuzumab Cyclophosphamide + Doxorubicin Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer Active, not recruiting USA 0
NCT01928589 Phase Ib/II Radiotherapy Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer Active, not recruiting USA 0
NCT01959490 Phase II Bevacizumab + Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Docetaxel + Trastuzumab Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer Completed USA 0
NCT01973309 Phase I Paclitaxel + Vantictumab A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer Completed USA 0
NCT02053636 Phase II Lucitanib A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer Completed ITA | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS 0
NCT02338349 Phase I Elacestrant A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer Completed USA 0
NCT02423902 Phase Ib/II Ad-RTS-IL-12 plus AL A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer Completed USA 0
NCT02450175 Phase I Letrozole Everolimus Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls Unknown status USA 0
NCT02509507 Phase I Pembrolizumab + Talimogene laherparepvec Talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Completed USA | POL | ESP | DEU | CHE | BEL | AUT | AUS 1
NCT02632071 Phase I Nab-paclitaxel + Ricolinostat Phase I of ACY-1215 + Nab-paclitaxel in Breast Cancer Completed USA 0
NCT02833233 Phase I Ipilimumab + Nivolumab A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer Completed USA 0
NCT02952729 Phase I XMT-1522 Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2 Completed USA 0
NCT02964507 Phase II Fulvestrant Fulvestrant + Molibresib Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer Terminated USA | GBR | FRA | ESP | CAN | AUS 1
NCT03094052 Phase II Neratinib Loperamide Crofelemer Neratinib + Trastuzumab Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Completed USA 0
NCT03199885 Phase III Atezolizumab + Paclitaxel + Pertuzumab + Trastuzumab Paclitaxel + Pertuzumab + Trastuzumab Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Active, not recruiting USA | CAN 0
NCT03284957 Phase Ib/II Amcenestrant Alpelisib + Amcenestrant Amcenestrant + Palbociclib Abemaciclib + Amcenestrant Amcenestrant + Everolimus Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer (AMEERA-1) Active, not recruiting USA | POL | ITA | GBR | FRA | ESP | CZE | CAN | BEL 1
NCT03432741 Phase I Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Suspended USA 0
NCT03767335 Phase I Fulvestrant + MEN1611 + Trastuzumab MEN1611 + Trastuzumab MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer (B-PRECISE-01) Completed USA | ITA | GBR | FRA | ESP | BEL 0
NCT03778931 Phase III Letrozole Exemestane Elacestrant Fulvestrant Anastrozole Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) Completed USA | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | CAN | BEL | AUT | AUS | ARG 2
NCT03802604 Phase I Atezolizumab + Talimogene laherparepvec Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO) Active, not recruiting ESP 0
NCT04176757 Phase I ZN-c5 A Study of ZN-c5 in Participants With Breast Cancer Completed USA | AUS 1
NCT04197687 Phase II Ado-trastuzumab emtansine + Sargramostim + TPIV100 Ado-trastuzumab emtansine + Sargramostim Pertuzumab + Trastuzumab Ado-trastuzumab emtansine TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery Recruiting USA 0
NCT04261218 Phase I Paclitaxel + Tomivosertib Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer Completed CAN 0
NCT04669587 Phase Ib/II ZB716 Palbociclib + ZB716 ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) (ENZENO) Unknown status USA 1
NCT04759248 Phase II Atezolizumab + Trastuzumab + Vinorelbine Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer (ATREZZO) Recruiting ESP 0
NCT05128773 Phase III Tamoxifen Amcenestrant Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity (AMEERA-6) Terminated 2
NCT05954143 Phase II BDC-1001 + Pertuzumab BDC-1001 Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Active, not recruiting USA | ESP 0
NCT05982093 Phase II Elacestrant Elacestrant + Triptorelin Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer (SOLTI-2104) Recruiting ESP 0
NCT06369285 Phase II Alisertib + Anastrozole Alisertib + Letrozole Alisertib + Fulvestrant Alisertib + Tamoxifen Alisertib + Exemestane A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1) Recruiting USA 0